InNexus Bio DXL Antibody Technology Causes Cancer Cell Death By Mechanisms Not Seen with Current Market-Leading Medications
Results Published In Journal of Anti-Cancer Drugs
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Mar 23, 2010 - InNexus Biotechnology Inc. (TSX:IXS.V) (http://www.ixsbio.com), commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announces the Journal of Anti-Cancer Drugs is publishing the manuscript titled, “The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis” by Bingaman et al.
The manuscript showcases in detail how InNexus' lead product, DXL625 (anti-CD20) induces apoptosis (cell death) in cancer cells, having a mechanism not previously seen with commercially available antibody drugs including Rituxan®. Comparison experiments were also conducted with Rituxan® to confirm this unique cell killing ability.
“DXL625 was found to be superior in (1) inhibiting growth of lymphoma cells and (2) directly inducing lymphoma cell death,” said Dr. Thomas Kindt, InNexus' Chief Scientific Officer. “Treatment with DXL625, even in the absence of any secondary immune mechanisms, elicited significant levels of lymphoma cell apoptosis, while equivalent treatment with the commercially available alternative did not.”
“Our manuscript provides wonderful insight into our DXL™ technology and is indeed a testament to the accomplishments of our scientific team and the value of their work toward the advancement of cancer research,” said Jeff Morhet, Chief Executive Officer of InNexus. “We look forward to advancing DXL625 to Phase I clinical trials and look forward to the team's continued success through 2010 and beyond.”
The manuscript is available now for download in the Published Ahead of Print section of the Journal's website.
About the Journal of Anti-Cancer Drugs
Anti-Cancer Drugs (on the web at http://journals.lww.com/anti-cancerdrugs) reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.
About InNexus Biotechnology
InNexus Biotechnology Inc. is a public biotechnology company commercializing the next generation of monoclonal antibodies based on its DXL™ and Transmab™ technology to improve the potency of existing antibodies and to develop novel antibodies based on the unique and patented methods and technologies of InNexus. Headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic, InNexus has its own in-house developmental (GLP) and manufacturing (GMP) facilities, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. InNexus Biotechnology Inc. is listed on the TSX Venture Exchange (TSX.V:IXS). Please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.
Rituxan® is a registered trademark of Biogen Idec Inc.
Contact: InNexus Biotechnology Inc.
Jeff Morhet, Chairman & Chief Executive Officer
Dr. Thomas Kindt, Chief Scientific Officer
Posted: March 2010